98%
921
2 minutes
20
Our systematic review aimed to assess the effectiveness and suitability of holmium laser enucleation of the prostate (HoLEP) as a treatment for benign prostatic hyperplasia (BPH) in comparison to transurethral resection of the prostate (TURP). We analyzed 12 studies involving male participants aged 45-85 years, all of whom had BPH. In our analysis, we compared HoLEP and TURP, with a focus on several primary outcomes, including postoperative International Prostate Symptom Score (IPSS), postvoid residual (PVR) volume, maximum flow rate (Qmax), and changes in sexual function post-treatment. HoLEP demonstrated advantages in certain aspects when compared to TURP. HoLEP generally resulted in an improved postoperative IPSS in some studies, but not all studies showed a significant difference when compared to TURP. HoLEP was associated with improved Qmax in most studies, but one study found no significant difference between HoLEP and TURP. Patients who underwent HoLEP showed improvement in the PVR volume in some studies, while others found no significant change in the PVR volume with either HoLEP or TURP. Some studies reported a reduction in orgasm and ejaculatory scores following TURP, while no significant changes were observed in erectile function, intercourse satisfaction, and overall satisfaction scores. It is worth noting that previous reviews and meta-analyses had limited data on the effects of HoLEP and TURP on sexual dysfunction. TURP is associated with a higher risk of morbidity and mortality, which has led to its replacement with HoLEP as the gold standard for treating BPH, particularly due to its size-independent applicability. HoLEP also demonstrated greater efficacy in the postoperative period.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613322 | PMC |
http://dx.doi.org/10.7759/cureus.46173 | DOI Listing |
Scand J Urol
September 2025
Boston Scientific Corporation, Marlborough, MA, USA.
Objectives: This capacity and budget impact analysis considers implications of offering a more diversified benign prostate enlargement (BPE) surgical care offering from a healthcare payer perspective in Sweden, Denmark, Norway and Finland.
Methods: A cohort simulation model compares 4-year treatment costs and capacity impact, including hospital bed-days and operating time, with Transurethral Resection of the Prostate (TURP), Holmium Laser Enucleation of the Prostate (HoLEP) using MOSES™Technology, photoselective vaporisation of the prostate (PVP) and Rezūm™ Water Vapour Therapy (WVTT). Current treatment choice is compared to a hypothetical scenario, where TURP-proportion is reduced to 50% and volumes of HoLEP, PVP and WVTT are increased.
Investig Clin Urol
September 2025
Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Purpose: This study aimed to compare the clinical outcomes of Aquablation and Holmium Laser Enucleation of the Prostate (HoLEP) for the treatment of benign prostatic hyperplasia (BPH), with emphasis on functional improvement, ejaculatory preservation, and perioperative safety.
Materials And Methods: We retrospectively analyzed data from January 2023 to March 2024, excluding patients with follow-up shorter than 3 months. Propensity score matching was performed using age, prostate volume, and preoperative prostate-specific antigen (PSA).
Cent European J Urol
May 2025
Department of Urology, University Hospital Southampton, London, United Kingdom.
Introduction: Holmium laser enucleation of the prostate (HoLEP) is a versatile treatment for benign prostatic hyperplasia (BPH), serving as an alternative to transurethral resection of the prostate (TURP) and open/robotic-assisted prostatectomy. Recent advancements have focused on evaluating the impact of smaller (22-24 Fr) vs larger (26-28 Fr) resectoscope sheaths on procedural outcomes.The aim of this study was to assess and compare the safety, efficiency, and complication rates associated with smaller and larger resectoscope sheaths in HoLEP procedures through a meta-analysis.
View Article and Find Full Text PDFWorld J Urol
August 2025
Desai Sethi Urology Institute, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA.
Introduction: Acquired bladder diverticulum (BD) is typically managed using open, laparoscopic, or robotic approaches. Although transurethral techniques demonstrated favorable outcomes in the 1970s and 1980s, they have largely fallen out of favor. This study revisits transurethral endoscopic management of large, symptomatic BD, combined with Holmium laser enucleation of the prostate (HoLEP) for patients with benign prostatic obstruction (BPO) and coexisting BD.
View Article and Find Full Text PDFEur Urol Open Sci
September 2025
Department of Urology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Background And Objective: Holmium laser enucleation of the prostate (HoLEP) is a common surgical management option for localised prostate cancer (PCa). This review aims to ascertain the safety, and functional and pathological outcomes of active treatments (radical prostatectomy [RP], radiotherapy [RT], and focal therapy) for localised PCa after HoLEP.
Methods: A systematic review and meta-analysis (PROSPERO registration: CRD42024562687) was conducted, searching the Ovid (Medline) and Embase (Elsevier) databases until October 2024.